Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals

Thrombosis and Haemostasis

Volumn 84, Issue 2, 2000, Pages 278-285

  Berry, Christopher N ^a   Lunven, Catherine ^b   Lecoffre, Catherine ^b   Lainée, Pierre ^b   O'Connor, Stephen E ^b   André, Frédéric ^a   Roger, Bénédicte ^a   Garrigou Gadenne, Danielle ^a   Rouchouse, Alain ^a   Roome, Nigel O ^a   Vivan, Nathalie ^a  

^a SANOFI   (France)

^b Sanofi Synthélabo ^*

Author keywords

aPTT; Argatroban mixed micelles; Ecarin clotting time; Plasma levels; Thrombin time

Indexed keywords

ARGATROBAN; ECARIN; GLYCOCHOLATE SODIUM; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG HALF LIFE; FEMALE; MALE; MICELLE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIMATE; PRIORITY JOURNAL; RABBIT; RAT; THROMBIN TIME;

EID: 0033868417     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614008     Document Type: Article

References (28)

1. Maraganore JM, Thrombin, thrombin inhibitors and the arterial thrombotic process. Thromb Haemost 1993; 70: 208-11.
2. Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In, "Haemostasis and Thrombosis" (Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds). Churchill Livingstone, London, 1994, pp 477-90.
3. Erikson BI, Ekman S, Kälebo P, Zachrisson BZ, Bach D, Close P. Prevention of deep-vein-thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.
4. Erikson BI, Mouret P, Kälebo P, Baue M, Ekman S, Lindbrat S, Bach D, Close P. Recombinant hirudin, CGP 39393 (Revasc), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Haemostasis 1996; 26 (Supplement 3): 624.
5. Okamoto S, Hijikata A, Kikumoto R, Tonomara S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-6.
6. 2[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-arginyl]-2- piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
7. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72:381-6.
8. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996; 75: 154-60.
9. Fujioka K. The Effect of MD-805 on Experimental Acute Arterial Thrombosis in Relation to Vasoactive Prostanoids (TXA, and PGI,). J Jap Coll Angiol 1989; 29: 57-64.
10. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of Platelet-Rich Arterial Thrombosis by Selective Thrombin Inhibition. Circulation 1990; 81: 219-25.
11. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, "mixed" and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994: 113: 1209-14.
12. Berry CN, Girard D, Girardot C, Lochot S, Lunven C, Visconte C. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Hemost 1996; 22: 233-41.
13. Duval N, Lunven C, O'Brien DP, Grosset A, O'Connor SE, Berry CN. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin. Br J Pharmacol 1996; 118: 727-33.
14. Schumacher WA, Heran CL, Steinbacher TE. Low molecular weight heparin (Fragmin) and thrombin active site inhibitor (Argatroban) compared in experimental arterial thrombosis and bleeding time. J Cardiovascular Pharmacol 1996; 28: 19-25.
15. Steffen H, Schmidt D. U. S. Patent 4158 707 Chem Abst. 1979; 91: 96642 p.
16. Rosoff M, Serajuddin ATM. Solubilization of diazepam in bile salts and in sodium cholate-lecithin-water phases. Int J Pharm 1980; 10: 6362-70.
17. Supersaxo A, Hem WR, Steffen H. Mixed micelles as proliposomal, lymphotrophic drug carrier. Pharm Res 1991; 8: 1286-91.
18. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the solubilization of taxol. Pharm Res 1994; 11: 206-12.
19. Iida S, Komatsu T, Hirano T, Fujimura Y, Nakai H, Kitazawa K, Kumagai Y, Sato T, Hayashi K, Inokuchi K. Pharmacokinetic studies of argatroban (MD-805) in dogs and rabbits. Blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive intravenous administration of argatroban. Oyo Yakuri(Pharmacometrics) 1986; 32: 1171-27.
20. Berry CN, Lumen C, Girardot C, Lechaire I, Girard D. Charles M-C, Ferrari P, O'Brien DP. Ecarin dolling time: a predictive coagulation assay for the amithrombotic activity of argatrohan in the rat. Thromb Haemost 1998; 79: 228-33.
21. Peters RF, Lees CM, Milchell KA, Tweed MF, Talhol MD, Wallis RB. The characterisation of thrombus development in an improved model of arteriovenous shunt thrombosis in the rat and ihe effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprosl. Thromb Haemost 1991; 65: 268-74.
22. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, Berends F, Hammes WD, Rijnicrse JJMM, Sturk A. Monitoring anticoagulant therapy by activated partial thromnoplastin time: Hirudin assessment. Thromb Haemost 1994; 72: 685-92.
23. Schwarz RP, Becker JCP, Brooks RL, Joffrion JL, Knappenberger GD, Kogan TP, Kogan PW, McKinney AA. The preclinical and clinical pharmacology of Novaslun (argatrohan): a small-molecule, direct thrombin inhibitor. Clin Appl Thrombos Hemost 1997; 3: 1-15.
24. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A. Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-5.
25. Kher A, Al Dieri R, Hemker HC, Beguin S. Laboratory assessment of anti-thrombotic therapy: what tests and if so why? Haemost 1997; 27: 211-8.
26. Herrman JPR, Suryapranaia H, den Heijer P, Gabriel L, Kutryk MJB, Serruys PW. Argatrohan during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb Thrombolys 1996; 3: 367-73.
27. Bergougnan L, Caplain H, Dubruc C, Cabanis MJ, Marsac J. Pharmacodynamic and pharmacokinetic profile of argatrohan in healthy volunteers. Fund Clin Pharmacol 1997; 11: 17.
28. Callas DD, Farced J. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 1996; 83: 463-8.